Mithra Pharmaceuticals SA (0R91.L)

6,41 -0,09 (-1,31%) Alla chiusura: 06:18PM BST

Mithra Pharmaceuticals SA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Christophe Marechal	Co-CEO & CFO	N/D	N/D	N/D
Mr. Xavier Paoli M.Sc.	COO & Co-CEO	N/D	N/D	N/D
Dr. Graham K. Dixon Ph.D.	Chief Scientific Officer	N/D	N/D	1961
Mr. Alex Sokolowski	Head of Investor Relations	N/D	N/D	N/D
Fanny Rozenberg	Secretary of the Board & General Counsel	N/D	N/D	N/D
Fanny Storms	Compliance Officer	N/D	N/D	N/D
Mr. Frederique Depraetere	Communication Director	N/D	N/D	N/D
Ms. Catherine Lejeune	HR Director	N/D	N/D	N/D
Mr. Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	N/D	N/D	N/D
Prof. Jean-Michel Foidart M.D., Ph.D.	President of the Scientific Advisory Board & Executive Director	7,12k	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2016 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Mithra Pharmaceuticals SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.